Glucagon-like peptide 1 treatment reverses vascular remodelling by downregulating matrix metalloproteinase 1 expression through inhibition of the ERK1/2/NF-B signalling pathway
Cardiovasc Diabetol 21 , 42 (2022)
Whats more, a study published in 2024 in the journal Hypertension found that tirzepatide, the active ingredient in Mounjaro (a diabetes drug) and Zepbound (approved for weight loss), significantly lowered the systolic blood pressure of nearly 500 adults who had obesity and took the medication for about eight months
The estimated treatment differences (IcoSema versus icodec alone for icodec endpoints and IcoSema versus semaglutide alone for semaglutide endpoints) were transformed back to the original scale and presented as ratios with 90% CI
A study in female patients with obesity who were prescribed a 925 kcal diet for 16 weeks followed by a 12001500 kcal diet for 32 weeks showed 11% weight loss in the first 2 months with reductions in triglycerides and total cholesterol by 22.7% and 15.7% respectively [29]
Studies Show GLP-1 Weight-Loss Drugs Leading to Loss of Critical Lean Mass News provided by BodySpec Oct 02, 2023, 10:10 ET Body Composition Changes Must Be Closely Monitored While Taking These Drugs, Not Just the Number on the Scale